Replies to post #215257 on Biotech Values

[DewDiligence]

Re: ADXS assessment

…what is your take on yesterday’s [Jefferies] presentation?

There was a smattering of new information, primarily about ADXS-HOT; the (interim) CEO said ADXS will submit two INDs related to ADXS-HOT in 2018, each for a distinct cancer type, and that ADXS has already manufactured 10 distinct instantiations of HOT (i.e. 8 of these are for potential indications other than the two designated for an IND submission in 2018).

Do you think new CEO is better than old one?

The old CEO was burning cash at much too fast a pace and he was somewhat of a con man, IMO; however, it’s too soon to say whether cash burn will be materially reduced under the new (interim) CEO.

A related question: Why is ADXS not seeking to hire a permanent CEO (#msg-135546461)?

I think price will move upwards soon with approval of AT-014 (a novel her2/neu-directed cancer immunotherapy) for dogs. This pet-drug approval will provide some validation of ADXS platform.

I wouldn’t bank on regulatory approval for PETX (ADXS’ licensee for AT-014) being much of a driver for ADXS’ share price.

If stars are aligned we have multi-bagger here.

Of course, but ADXS hasn’t done much right lately. Almost every clinical and regulatory milestone for 2H17 has been missed, and the long delay in starting the ADXS-NEO phase-1 (#msg-134670005) is especially hard to fathom.

All told, I think ADXS is a pretty shaky company, but the low enterprise value, the intriguing Lm platform, and the apparent confidence of AMGN justify holding a modest position. I recently added shares at $3.18 (#msg-136019282).